Literature DB >> 2801677

Campylobacter pylori, NSAIDS, and smoking: risk factors for peptic ulcer disease.

D F Martin1, E Montgomery, A S Dobek, G A Patrissi, D A Peura.   

Abstract

Campylobacter pylori, nonsteroidal anti-inflammatory drugs, and smoking are associated with ulcer disease. To define further the role of these factors in ulcer disease, one hundred seven subjects presenting for endoscopy were tested for specific IgG and IgA antibodies to C. pylori, and questioned about nonsteroidal use and smoking. Sixty were dyspeptic patients, 28 were disease controls, and 19 were healthy asymptomatic volunteers. Considering all subjects, 81% (87/107) were either taking nonsteroidals or had antibody to C. pylori, and 32% of these (28/87) had an ulcer. Nineteen percent (20/107) were neither taking nonsteroidals nor had antibody to C. pylori, and none of these had an ulcer, p less than 0.01. Smokers, 41% (11/27), were more likely to have an ulcer than nonsmokers, 20% (16/80), p less than 0.05, but only because of the increased prevalence of ulcers in smokers who also had C. pylori, 73% (11/15) versus 27% (12/45) of nonsmokers with C. pylori, p less than 0.01. The use of nonsteroidals and antibody to C. pylori identify people at risk for ulcers. Smoking increases this risk in subjects with C. pylori. Absence of a history of nonsteroidal use and antibody to C. pylori identify individuals with a low probability of ulcer disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2801677

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  16 in total

1.  Helicobacter pylori supernatants cause epithelial cytoskeletal disruption that is bacterial strain and epithelial cell line dependent but not toxin VacA dependent.

Authors:  James R Bebb; Darren P Letley; Joanne L Rhead; John C Atherton
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

Review 2.  Helicobacter pylori and duodenal ulcer. Evidence suggesting causation.

Authors:  F Mégraud; H Lamouliatte
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

Review 3.  The clinical relevance of strain types of Helicobacter pylori.

Authors:  J C Atherton
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

4.  Potentiating effect of passive cigarette smoking on gastrointestinal damage induced by indomethacin in rats.

Authors:  X Guo; Q B Mei; C H Cho
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

5.  Helicobacter pylori upregulates matrilysin (MMP-7) in epithelial cells in vivo and in vitro in a Cag dependent manner.

Authors:  J R Bebb; D P Letley; R J Thomas; F Aviles; H M Collins; S A Watson; N M Hand; A Zaitoun; J C Atherton
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

6.  Serological diagnosis of Helicobacter pylori--evaluation of four tests in the presence or absence of non-steroidal anti-inflammatory drugs.

Authors:  A S Taha; J Reid; P Boothmann; C G Gemmell; F D Lee; R D Sturrock; R I Russell
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

7.  Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens.

Authors:  L Santucci; S Fiorucci; L Patoia; F M Di Matteo; P M Brunori; A Morelli
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

8.  Local gastric and serum amoxicillin concentrations after different oral application forms.

Authors:  M P Cooreman; P Krausgrill; K J Hengels
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

9.  Diagnostic tests for Helicobacter pylori: comparison and influence of non-steroidal anti-inflammatory drugs.

Authors:  A S Taha; P Boothman; I Nakshabendi; J Reid; C Morran; C G Gemmell; F D Lee; R D Sturrock; R I Russell
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

10.  Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs.

Authors:  N Hudson; M Balsitis; F Filipowicz; C J Hawkey
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.